How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and resource savings reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about sebetralstat

Marketing authorisation indication

2.1

Sebetralstat (Ekterly, KalVista) is indicated for 'the treatment of hereditary angioedema (HAE) attacks in adult and adolescents aged 12 years and older'.

Price

2.3

The list price of sebetralstat is £12,000 for a 300-mg pack of 6 tablets (including VAT, company submission).

2.4

The company has a commercial arrangement, which would have applied if sebetralstat had been recommended.

Carbon Reduction Plan

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for KalVista will be included here when guidance is published.